

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 2669
)
NEWCOMBE *et al.*)
)
Application No.: 10/507,081) Group Art Unit: 1624
)
Filed: September 9, 2004) Examiner: Deepak R. RAO
)
FOR: DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-)
(4-SULFOANILINO) PYRIMIDINE WITH)
CDK INHIBITORY ACTIVITY)
)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop AMENDMENT**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: **June 3, 2008**

Sir:

OK TO ENTER: /DR/

AMENDMENT AND RESPONSE AFTER FINAL

06/14/2008

In response to the Final Rejection mailed March 3, 2008, please amend the above-identified application as follows. As noted in the Remarks, these claim amendments are believed to overcome the remaining grounds for rejection and/or place the claims in better condition for appeal. Inasmuch no search or significant effort by the Examiner should be needed to consider these amendments, entry thereof after Final rejection is believed to be appropriate and is respectfully requested.

The Examiner's attention is directed to the Terminal Disclaimers submitted herewith with respect to each of Applications No. 10/507,163 and No. 10/507,169, which are discussed further below.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.